Difluoromethyl-pyridin-2-yltriazole

Abstract

The present invention provides GABA receptor agonists containing the α5 subunit that are useful for treating central nervous system disorders and other disorders. A The present invention relates to difluoromethyl-pyridin-2-yltriazoles of general formula (I), which are modulators of the receptor.Furthermore, the present invention relates to processes for preparing pharmaceutical compositions and for the manufacture of the compounds according to the invention.

Description

[Technical Field]

[0001] The present invention relates to GABA containing the α5 subunit. A The present invention relates to difluoromethyl-pyridin-2-yltriazoles of the general formula (I), which are modulators of the receptor. The compounds are useful for treating central nervous system and other diseases. Furthermore, the present invention relates to methods for preparing pharmaceutical compositions and methods for producing the compounds according to the present invention. [Background technology]

[0002] GABA A The α5 subunit has been suggested as a therapeutic target for the treatment of various diseases and disorders of the central nervous system. A A link between the α5 subunit and various neurological disorders, circadian rhythm disorders, and pain states has been established. A Compounds capable of modulating the receptor are expected to be particularly useful candidates for the treatment of, inter alia, cognitive disorders, Alzheimer's disease, schizophrenia, positive, negative and / or cognitive symptoms associated with schizophrenia, cognitive impairment associated with schizophrenia, and cognitive deficits associated with Down's syndrome, autism, neurofibromatosis type I or after stroke.

[0003] WO 2012 / 062687 (corresponding to EP 2638029) discloses triazole derivatives for treating neurological disorders. WO 2020 / 016443 discloses difluoromethyl-phenyltriazoles as GABA receptor modulators for treating nervous system disorders. The compounds contain a difluoromethyl group attached to a phenyl group linked to a triazole ring. The present invention describes difluoromethyl-pyridin-2-yltriazoles, which contain a difluoromethyl group attached to a 2-pyridine group linked to a triazole ring. The combination of the 2-pyridine group with the attached difluoromethyl group surprisingly results in significantly more potent GABAergic receptor agonists containing the α5 subunit than similar compounds described in WO 2020 / 016443. A This has led to compounds that are modulators of the receptor. The modulatory potency of the compound can be measured as the compound's K value in Assay A, described below. In this case, the combination of a pyridine group in place of the phenyl group used in the phenyltriazoles of WO 2020 / 016443 and a difluoromethyl group at the 4-position unexpectedly increases the potency of the claimed compounds, typically by at least about 10-fold or more. The effect is GABA A Related to the 5R binding constant Ki, increased potency translates into a lower effective dose of each compound in treating the disease. Summary of the Invention

[0004] Object of the invention Surprisingly, pyridin-2-yl-triazoles of general formula (I) [ka] (I) (In the formula, Xa and Xb are different from each other and represent C or N; R1 is a substituted phenyl or a 5- or 6-membered heterocyclyl ring containing 1, 2, or 3 heteroatoms. However, GABA A GABA receptor agonists have improved 5R binding properties, which can lead to lower doses of the compound and minimize side effects in disease treatment. A A potent negative modulator of 5R (i.e., GABA AFurthermore, the compounds of the present invention have excellent CNS penetration with low excretion rates from brain compartments, which is necessary for drugs with desired effects in the CNS and high metabolic stability.

[0005] Therefore, one aspect of the present invention is to A refers to a compound according to formula (I), or a salt thereof, that is a 5R negative modulator. Another aspect of the present invention is a method for treating GABA-rich A GABA with 5R binding properties A refers to a compound according to formula (I), or a pharmaceutically acceptable salt thereof, that is a negative modulator of 5R. Another aspect of the present invention is a method for treating GABA-rich A GABA, which has excellent CNS penetration with 5R binding properties, low excretion rate from brain compartments, and high metabolic stability. A refers to a compound according to formula (I), or a pharmaceutically acceptable salt thereof, that is a negative modulator of 5R.

[0006] Yet a further aspect of the present invention relates to pharmaceutical compositions containing at least one compound according to formula (I) or a pharmaceutically acceptable salt thereof, optionally together with one or more inert carriers and / or diluents. A further aspect of the present invention relates to methods for preparing the compounds of the present invention.

[0007] In particular, the present invention relates to a method for treating acute neurological disorders, chronic neurological disorders, cognitive impairment, Alzheimer's disease, memory deficits, schizophrenia, positive, negative and / or cognitive symptoms associated with schizophrenia, cognitive impairment associated with schizophrenia, bipolar disorder, autism, Down's syndrome, neurofibromatosis type I, post-operative cognitive decline, sleep disorders, circadian rhythm disorders, amyotrophic lateral sclerosis, AIDS-induced dementia, psychotic disorders, substance-induced psychotic disorders, anxiety disorders, generalized anxiety disorder, panic disorder, delusional disorder, obsessive-compulsive disorder, acute stress disorder, drug dependence, movement disorders, Parkinson's disease, restless legs syndrome, cognitive deficit disorders, multi-infarct dementia, rheumatoid arthritis ... GABA-dependent neuropathic pain, including disorders of the nervous system, depression, major depressive disorder, neuropsychiatric conditions, psychosis, attention deficit hyperactivity disorder, neuropathic pain, stroke, attention disorders, eating disorders, anorexia, anorexia nervosa, cachexia, weight loss, muscle atrophy, pain conditions, chronic pain, nociceptive pain, post-operative pain, knee osteoarthritis pain, rheumatoid arthritis pain, musculoskeletal pain, burn pain, eye pain, inflammatory pain, fracture pain, hyperalgesia, neuropathic pain, herpes-related pain, HIV-associated neuropathic pain, traumatic nerve injury, traumatic brain injury recovery, post-stroke pain, post-ischemic pain, fibromyalgia, chronic headache, migraine, tension headache, diabetic neuropathic pain, phantom limb pain, visceral pain, and cutaneous pain. A The present invention relates to a compound according to formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound according to formula (I) or a pharmaceutically acceptable salt thereof, for use in the prevention and / or treatment of diseases or conditions that may be affected by negative regulation of 5R. Other results or consequences of the present invention will be apparent to those skilled in the art directly from the foregoing and following description. DETAILED DESCRIPTION OF THE INVENTION

[0008] The present invention relates to compounds of general formula (I) [ka] (I) or a salt thereof. (In the formula, Xa and Xb are different from each other and represent C or N; R1 is a substituted phenyl or a 5- or 6-membered substituted heterocyclyl ring containing 1, 2, or 3 heteroatoms.

[0009] In particular, either Xa or Xb is C. R1 is preferably carbamoyl-substituted phenyl, unsubstituted 2-pyridones or substituted with halogens such as fluorine or substituted on the nitrogen by methyl or ethyl; 2, 3 or 4-pyridyl substituted by cyano-(NC-) or thiomethylato-, amino-, methylamino-, methylsulfonyl- or halogen, Unsubstituted pyrimidinyl-, or C 1-6 -alkyl-, amino-, -hydroxymethyl-substituted pyrimidinyl-, or pyrazinyl- or pyridazinyl, C 1-6 -alkyl- or pyrrolyl- substituted with NC-CH2-CH2-, and C 1-6 -Alkyl-, C 3-5 -cycloalkyl-, N-C-CH2-CH2-, amino-, methyl-amino- or pyrazolyl- substituted with halogen, C 1-6 imidazoly- substituted by -alkyl-, carbamoyl-, NC—CH2—CH2-, amino- or -methylamino-, C, such as unsubstituted triazolyl- or methyl 1-3 -alkyl-substituted triazolyl-, methyl-substituted oxazolyl- and thiophenyl-substituted with N-C-CH2-CH2-; is selected from the group consisting of:

[0010] Unless otherwise specified, groups, residues, and substituents, especially R1, are defined as above and below. If residues, substituents, or groups occur several times in a compound, they may have the same or different meanings. Some preferred meanings for groups and substituents of the compounds according to the invention are given below. In a further embodiment of the invention, R1 is Carbamoyl-substituted phenyl, e.g.

[0011] [ka] and Unsubstituted 2-pyridones or 2-pyridones substituted with halogens such as fluorine or methyl or ethyl on the nitrogen, e.g.

[0012] [ka] is selected from the group consisting of: In a further embodiment of the invention, R1 is NC- or -thiomethylato-, amino-, methylamino- or -methylsulfonyl or halogen-substituted 2-, 3- or 4-pyridyl, for example

[0013] [ka] is.

[0014] In a further embodiment of the invention, R1 is selected from the group consisting of the compounds of claim 1 or salts thereof, Unsubstituted pyrimidinyl-, or C 1-6 -alkyl-, amino-, -hydroxymethyl-substituted pyrimidinyl-, or pyrazinyl- or pyridazinyl, for example

[0015] [ka] is.

[0016] In a further embodiment of the invention, R1 is C 1-6 -alkyl- or pyrrolyl- substituted with NC-CH2-CH2-, and C 1-6 -Alkyl-, C 3-5-cycloalkyl-, N-C-CH2-CH2-, -amino, -methyl-amino, or -pyrazolyl substituted with halogen, for example

[0017] [ka] [ka] is.

[0018] In a further embodiment of the invention, R1 is C 1-6 imidazoly- substituted with -alkyl-, carbamoyl, NC-CH2-CH2-, amino- or -methylamino-, for example [ka] is.

[0019] In a further embodiment of the invention, R1 is Unsubstituted triazolyl- or C 1-3 -alkyl-substituted triazolyl-, e.g. [ka] is.

[0020] Furthermore, in a further embodiment of the present invention, R1 is methyl-substituted oxazolyl- or thiophenyl-substituted with N—C—CH—CH—, e.g.

[0021] [ka] is.

[0022] More preferred are the following compounds listed in Table 1: [Table 1] TIFF0007802256000013.tif218147 TIFF0007802256000014.tif223149 TIFF0007802256000015.tif223149 TIFF0007802256000016.tif223149 TIFF0007802256000017.tif223149 TIFF0007802256000018.tif218144 TIFF0007802256000019.tif223147 TIFF0007802256000020.tif218144 TIFF0007802256000021.tif223149 TIFF0007802256000022.tif223149 TIFF0007802256000023.tif223149 TIFF0007802256000024.tif218147 TIFF0007802256000025.tif229149 TIFF0007802256000026.tif223149 TIFF0007802256000027.tif223147 TIFF0007802256000028.tif223150 TIFF0007802256000029.tif223148 TIFF0007802256000030.tif151144 Some terms used above and below to describe the compounds according to the invention are now defined in more detail.

[0023] Terms not specifically defined herein should be given the meaning that would be given to them by one of ordinary skill in the art in light of the disclosure and context. However, as used herein, unless expressly stated to the contrary, the following terms have the meaning indicated and the following definitions are to be adhered to.

[0024] In the groups, radicals, or moieties defined below, the number of carbon atoms is often specified before the group, e.g., C 1-6 -Alkyl means an alkyl group or radical having 1 to 6 carbon atoms. Generally, for groups such as HO-, H2N-, (O)S-, (O)2S-, NC-(cyano), HOOC-, F3C-, or the like, one skilled in the art will recognize the point of attachment of the group to the molecule from the free valence of the group itself. In combined groups containing two or more subgroups, the last listed subgroup is the point of attachment of the group, e.g., the substituent "aryl-C 1-3 -Alkyl-" is C 1-3 -an aryl group bonded to an alkyl- group, the latter of which is bonded to the core or group to which the substituent is bonded.

[0025] In general, the site of attachment of a given residue to another group is intended to be variable, i.e., any possible atom within the residue that has a replaceable hydrogen may be the point of attachment for the group to be attached, unless otherwise indicated. When a compound of the present invention is depicted in the form of a chemical name and as a formula, the formula shall prevail in the event of any discrepancy. Unless otherwise indicated, throughout this specification and the appended claims, a given chemical formula or chemical name is intended to encompass tautomers and all stereo, optical, and geometric isomers (e.g., enantiomers, diastereomers, E / Z isomers, etc.) as well as racemates thereof, as well as mixtures of different proportions of the separate enantiomers, mixtures of diastereomers, or mixtures of any of the above forms, wherein such isomers and enantiomers also exist as salts, including pharmaceutically acceptable salts, and as solvates, such as, for example, hydrates, of the free compounds or of the salts of the compounds.

[0026] The phrases "pharmaceutically acceptable" or "physiologically acceptable" are used herein to refer to compounds, substances, compositions, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds in which the parent compound has been modified by making an acid or base salt thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids, and the like. For example, such salts include salts derived from benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gentisic acid, hydrobromic acid, hydrochloric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, 4-methyl-benzenesulfonic acid, phosphoric acid, salicylic acid, succinic acid, sulfuric acid, and tartaric acid.

[0027] Further pharmaceutically acceptable salts can be formed with cations derived from ammonia, L-arginine, calcium, 2,2'-iminobisethanol, L-lysine, magnesium, N-methyl-D-glucamine, potassium, sodium and tris(hydroxymethyl)-aminomethane. The pharmaceutically acceptable salts of the present invention can be synthesized from parent compounds containing a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base form of these compounds with a sufficient amount of a suitable base or acid in water or an organic diluent such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof. Acid salts other than those mentioned above (e.g., trifluoroacetate salts), which are useful, for example, for purifying or isolating the compounds of the present invention, also form part of the present invention.

[0028] The term "substituted," as used herein, means that any one or more hydrogens at the designated atom are replaced with one selected from the indicated group, provided that the replacement does not exceed the number of available valence electrons at the designated atom and that the replacement results in a stable compound. The term "partially unsaturated," as used herein, means that there are one, two, or more, preferably one or two, double bonds in the specified group or moiety. Preferably, as used herein, the term "partially unsaturated" does not include fully unsaturated groups or moieties. The term "halogen" generally refers to fluorine (F), chlorine (Cl), bromine (Br) and iodine (I).

[0029] The term "C" either alone or in combination with another group, wherein n is an integer from 2 to n. 1-n "-alkyl" refers to an acyclic, saturated, branched or straight-chain hydrocarbon group having 1 to n C atoms. For example, the term C 1-5-Alkyl is the group H3C-, H3C-CH2-, H3C-CH2-CH2-, H3C-CH(CH3)-, H3C-CH2-CH2-CH2-, H3C-CH2-CH(CH3)-, H3C-CH(CH3)-CH2-, H3C-C(CH3)2-, H3C-CH2-CH2-CH2-CH2-, H3C- CH2-CH2-CH(CH3)-, H3C-CH2-CH(CH3)-CH2-, H3C-CH(CH3)-CH2-CH2-, H3C-CH2-C(CH3)2-, H3C-C(CH3)2-CH2-, H3C-CH(CH3)-CH(CH3)- and H3C-CH2-CH(CH2CH3)-.

[0030] The term "C" either alone or in combination with another group, wherein n is an integer from 4 to n. 3-n "-cycloalkyl" refers to a cyclic, saturated, unbranched hydrocarbon group having 3 to n C atoms. For example, the term C 3-7 -Cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

[0031] Many of the above-given terms may be used repeatedly in the definitions of formulae or groups and have, independently of each other, one of the meanings above-given in each case.

[0032] The compounds according to the invention can be obtained using synthetic methods known in principle. Preferably, the compounds are obtained by the following methods according to the invention, which are described in more detail below. The basic chemical synthesis route used for the compounds disclosed herein is: Route 1: [ka] [ka]

[0033] Route 2: [ka]

change

[0034] abbreviation Table 2 Analytical HPLC methods Method A

[0035] Table 3 Method B

[0036] Table 4 Method C

[0037] Table 5 Method D

[0038] Table 6 Method E

[0039] Table 7 Method F

[0040] Table 8 Method G

[0041] Table 9 Method H

[0042] [Table 10] Method I

[0043] [Table 11] Method J

[0044] [Table 12] Method K [Table 13] Method L

[0045] [Table 14] Method M

[0046] [Table 15] Method N

[0047] [Table 16]

[0048] Preparation of starting compounds I-XVIII Example I :[3-(5-difluoromethyl-pyridin-2-yl)-5-methyl-3H-[1,2,3]triazol-4-yl]-methanol

[0049] [ka] A solution of 2-azido-5-difluoromethyl-pyridine (25.7 g, 151 mmol) in 50 mL of but-2-an-1-ol is stirred at 120° C. for 5 days. Excess alcohol is evaporated as much as possible in vacuo. Column chromatography on silica gel using DCM / acetone (10:1) as the eluent gives 9.00 g of 3-(5-difluoromethyl-pyridin-2-yl)-5-methyl-3H-[1,2,3]triazol-4-yl]-methanol as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 2.32 - 2.43 (m, 3 H) 4.86 (s, 2 H) 7.26 (t, J=56Hz 1 H) 8.11 (d, J=8.59 Hz, 1 H) 8.31 (s, 1 H) 8.84 (d, J=0.76 Hz, 1H)

[0050] Example II :2-Bromo-5-(difluoromethyl)pyridine [ka] To a solution of 6-bromo-pyridine-3-carbaldehyde (186 g, 1.00 mol) in 1.86 L of dichloromethane at 0 °C, diethylaminosulfur trifluoride (185 ml, 1.40 mol) is added dropwise. The mixture is stirred at rt for 18 h. The reaction mixture is poured onto ice and saturated NaHCO . The aqueous phase is extracted three times with DCM. The combined organic layers are dried over Na SO , filtered and concentrated. The residue is purified by column chromatography (silica gel, hexane / EE (4 / 1)) to give 170 g of product.

[0051] C6H4BrF2N (M=208.0g / mol) ESI-MS: 208[M+H] + 1H NMR (DMSO-d6, 400 MHz): δ = 8.65 (d, J = 1.3 Hz, 1H), 7.91-8.08 (m, 1H), 7.76-7.92 ppm (m, 1H), 7.17 (t, J = 56 Hz, 1H)

[0052] Example III :5-(Difluoromethyl)-2-[2-(trimethylsilyl)ethynyl]pyridine [ka] To a solution of a mixture of Example II (120 g, 0.58 mol), bis(triphenylphosphine)palladium(II) chloride (20.2 g, 0.03 mol), copper(I) iodide (5.49 g, 0.03 mol), and triethylamine (250 mL, 1.73 mol) in 600 mL of tetrahydrofuran at 0 °C, ethynyl-trimethyl-silane (160 mL, 1.15 mol) was added dropwise. The resulting mixture was stirred at RT for 18 h. The mixture was filtered through Celite. The cake was washed with EtOAc. The filtrate was washed with water, dried over Na2SO4, filtered, and concentrated. Purification by column chromatography (silica gel, hexane / EE (19 / 1)) gave 117 g of product.

[0053] C 11 H 13 FNSi (M=225.3g / mol) ESI-MS: 226[M+H] + 1 H NMR (DMSO-d6, 400 MHz): δ = 8.76 (d, J = 0.8 Hz, 1H), 8.01 (dt, J = 8.1, 0.9 Hz, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.16 (t, J = 56 Hz, 1H) 0.23-0.30 ppm (m, 9H)

[0054] Example IV :5-Difluoromethyl-2-ethynyl-pyridine [ka] To a solution of Example III (100.0 g, 0.42 mol) in 800 mL of tetrahydrofuran, water (15.0 mL, 834 mmol) is added. The resulting solution is cooled to 0°C, and then a 1.0 M solution of tetrabutylammonium fluoride in THF (143 mL, 0.50 mol) is added dropwise. After 1 hour, TLC showed that the reaction was complete. Water was added, and the aqueous layer was extracted three times with diethyl ether. The combined organic layers were dried, filtered, and carefully concentrated. The residue was purified by column chromatography (silica gel, hexane / DCM (1 / 1 to 0 / 1)) to give the product.

[0055] C8H5F2N (M=153.1g / mol) ESI-MS: 154[M+H] + 1 H NMR (DMSO-d6, 400 MHz): δ = 8.77 (d, J = 0.8 Hz, 1H), 8.03 (br d, J = 8.1 Hz, 1H), 7.72 (d, J = 8.1 Hz, 1H), 7.17 (t, J = 56 Hz, 1H) 4.50 ppm (s, 1H)

[0056] Example V :5-Difluoromethyl-2-(1-trimethylsilanylmethyl-1H-[1,2,3]triazol-4-yl)-pyridine

[0057] [ka] To a solution of Example IV (50.0 g, 0.30 mol) in 1.5 L of DMF was added copper(I) iodide (10.9 g, 0.06 mol) and N,N-diisopropylethylamine (50.360 mL, 0.29 mol), followed by dropwise addition of trimethylsilylmethyl azide (50.6 mL, 0.34 mol). The resulting mixture was stirred at rt for 24 h. The reaction was quenched by the addition of water / brine, followed by addition of EtOAc, and the mixture was filtered through Celite. The filtrate was extracted three times with EtOAc, dried over Na2SO4, filtered, and concentrated. Purification by column chromatography (silica gel, hexane / EE (3 / 1)), followed by trituration of the solid with pentane and drying, gave 68.0 g of product.

[0058] C 12 H 16 F2N4Si (M=282.4g / mol) ESI-MS: 283[M+H] + R t (HPLC): 3.52 minutes (Method M) 1 H NMR (DMSO-d6, 400 MHz): δ = 8.78 (s, 1H), 8.52 (s, 1H), 8.13-8.20 (m, 1H), 8.05-8.12 (m, 1H), 7.17 (t, J = 56 Hz, 1H) 4.10 (s, 2H), 0.11 ppm (s, 9H)

[0059] Example VI 5-Difluoromethyl-2-(1-methyl-1H-[1,2,3]triazol-4-yl)-pyridine [ka] To a solution of Example V (93.0 g, 0.33 mol) in 1.86 L of tetrahydrofuran, water (11.9 ml, 0.66 mol) is added. The resulting solution is cooled to 0° C., and tetrabutylammonium fluoride (395.2 ml, 0.40 mol) is added dropwise. The reaction mixture is stirred at 0° C. for 1.5 hours. Water is added, and the THF is evaporated. The precipitate formed is filtered, washed with water, and dried to give 51.0 g of product.

[0060] C9H8F2N4 (M = 210.1 g / mol) ESI-MS: 211[M+H] + 1 H NMR (DMSO-d6, 400 MHz): δ = 8.80 (d, J = 1.0 Hz, 1H), 8.65 (s, 1H), 8.14-8.19 (m, 1H), 8.03-8.13 (m, 1H), 7.17 (t, J = 56 Hz, 1H), 4.13 ppm (s, 3H)

[0061] Example VII :5-(5-difluoromethyl-pyridin-2-yl)-3-methyl-3H-[1,2,3]triazole-4-carbaldehyde [ka] To a solution of Example VI (40.0 g, 0.19 mol) in 1.2 L of tetrahydrofuran at −65° C., a 2.5 M solution of N-butyllithium (114.2 mL, 0.29 mol) in hexane was added dropwise. The resulting mixture was stirred at this temperature for 1.5 h. N,N-dimethylformamide (147.4 mL, 1.90 mol) was then added dropwise, and the reaction mixture was then stirred at 0° C. for 30 min. The reaction was quenched by the slow addition of aqueous NH4Cl. The aqueous layer was extracted three times with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated. Purification by column chromatography (silica gel, DCM / EE (7 / 3 to 5 / 5)), followed by trituration with pentane, gave 19.9 g of product.

[0062] C9H8F2N4 (M = 238.2 g / mol) ESI-MS: 239[M+H] + R t (HPLC): 2.68 minutes (Method M) 1 H NMR (DMSO-d6, 400 MHz): δ = 10.68 (s, 1H), 8.92 (d, J = 0.8 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 8.22 (dd, J = 8.1, 1.0 Hz, 1H), 7.23 (t, J = 56 Hz, 1H), 4.29 ppm (s, 3H)

[0063] Example VIII :5-(5-difluoromethyl-pyridin-2-yl)-3-methyl-3H-[1,2,3]triazole-4-carbaldehyde

[0064] [ka] Example VII (19.9 g, 0.08 mol) is dissolved in 199 mL of methanol and 99.5 mL of tetrahydrofuran. The resulting solution is cooled to 0° C. Sodium borohydride (6.32 g, 0.17 mol) is then added portionwise, and the reaction mixture is stirred at this temperature for 2 hours. The reaction is quenched by the addition of water. MeOH is evaporated, and the resulting precipitate is collected by filtration, washed with water, and dried. The solid is triturated with pentane to give 19.4 g of product.

[0065] C9H8F2N4 (M = 240.2 g / mol) ESI-MS: 241[M+H] + R t (HPLC): 3.52 minutes (Method N) 1H NMR (DMSO-d6, 400 MHz): δ = 8.83 (s, 1H), 8.22 (d, J = 8.1 Hz, 1H), 8.11 (br d, J = 8.1 Hz, 1H), 7.18 (t, J = 56 Hz, 1H), 5.53 (s, 1H), 5.09 (d, J = 3.8 Hz, 2H), 4.11 ppm (s, 3H)

[0066] Example IX.1 : 3-[3-(5-difluoromethyl-pyridin-2-yl)-5-methyl-3H-[1,2,3]triazol-4-ylmethoxy]-6-iodo-pyridazine

[0067] [ka] To a solution of Example I (4.00 g, 16.6 mmol) in 50 mL of THF, sodium hydride (1.10 g, 25.0 mmol) and 3,6-diiodo-pyridazine (5.50 g, 17.0 mmol) are added. The reaction mixture is stirred at 80° C. overnight. The reaction mixture is evaporated. The residue is quenched with water and the product is extracted with DCM. The organic phases are combined, dried over MgSO4, and evaporated. The crude product is purified by column chromatography (silica gel, CH / EE (6 / 4)) to give 6.30 g of product.

[0068] C 14 H 11 F 2I NO (M=444.2g / mol) ESI-MS: 445[M+H] + R t (HPLC): 0.57 min (Method A) 1H NMR (DMSO-d6, 400 MHz): δ = 8.53-8.80 (m, 1H), 8.33 (dt, J = 8.5, 1.1 Hz, 1H), 7.96 (d, J = 9.1 Hz, 1H), 7.22 (t, J = 52 Hz, 1H), 6.95 (d, J = 9.1 Hz, 1H), 5.95 (s, 2H), 2.36-2.45 ppm (m, 3H)

[0069] Examples IX.2 to IX.4, referred to in the following table for compounds of Examples IX.2 to IX.4, are prepared according to the general procedure of Example IX.1 described above. [Table 17] The reaction conditions mentioned in the table below were used for Examples IX.2 to IX.4.

[0070] [Table 18]

[0071] (Example X.1) :1-(6-chloropyridazin-3-yl)-1H-pyrazole-4-carbonitrile [ka] To a solution of 4-cyanopyrazole (312 mg, 3.40 mmol) in 5 mL of DMF, 3,6-dichloropyridazine (500 mg, 3.40 mmol) and potassium carbonate (1.40 g, 10.1 mmol) are added, and the reaction mixture is stirred overnight at RT. The mixture is quenched with ice water, and the precipitate is filtered. The residue is washed with water, and the isolated solid is dried in a vacuum drying cabinet to give 524 mg of product. C8H4ClN5 (M = 205.6 g / mol) ESI-MS: 206 [M+H] + R t (HPLC): 0.80 min (Method C)

[0072] The following compounds are prepared according to the general procedure of Example X.1 described above. [Table 19]

[0073] Example XI : 3-chloro-6-(5-methyl-1H-1,2,4-triazol-1-yl)pyridazine [ka] 6-Chloro-pyridazin-3-yl)-hydrazine (16.4 g, 113 mmol) and N-[1-dimethylamino-meth-(E)-ylidene]-acetamide (15.5 g, 136 mmol) are dissolved in 164 mL of acetic acid. The mixture is placed in a preheated oil bath at 80 °C. The reaction is stirred at this temperature for 30 minutes (TLC monitoring), and the acetic acid is evaporated in vacuo. The residue is dissolved in EtOAc, and the organic layer is slowly neutralized with NaHCO3 (concentrated aqueous solution). The organic layer is dried over Na2SO4, and the solvent is evaporated. The product is purified on silica gel using EtOAc / hexane (3:1) as the eluent. 10.2 g of 3-chloro-6-(5-methyl-[1,2,4]triazol-1-yl)-pyridazine is obtained as a cream solid.

[0074] Example XII :Methyl 1-(6-chloropyridazin-3-yl)-1H-imidazole-4-carboxylate [ka] To a solution of sodium hydride (1.74 g, 43.6 mmol) in 50 mL of DMF is added methyl 1H-imidazole-4-carboxylate (5.00 g, 39.6 mmol) at 0 °C. The reaction mixture is stirred for 30 minutes. To the reaction mixture is added a solution of 3,6-dichloropyridazine (5.90 g, 39.6 mmol) in 30 mL of DMF at 0 °C, and the mixture is stirred for 20 hours to reach RT. The reaction mixture is quenched with water under ice cooling, and the precipitate is filtered, washed, and dried to give 3.90 g of product.

[0075] C9H7ClN4O2 (M=238.6g / mol) ESI-MS: 239[M+H] + 1 H NMR (400 MHz, DMSO-d6) δ = 8.74 (d, J = 1.3 Hz, 1H), 8.72 (d, J = 1.0 Hz, 1H), 8.43 (d, J = 9.3 Hz, 1H), 8.25 (d, J = 9.3 Hz, 1H), 3.82 (s, 3H)

[0076] Example XIII :1-(6-chloropyridazin-3-yl)-1H-imidazole-4-carboxylic acid [ka] To a solution of Example XII (3.80 g, 15.8 mmol) in 100 mL of 1,4-dioxane, add 1 M NaOH (16.0 mL, 16.0 mmol) and stir at RT for 18 hours. The reaction mixture is quenched with ice and 1 M HCl (16.0 mL, 16.0 mmol). The precipitate is filtered, washed, and dried to give 3.30 g of product.

[0077] C8H5ClN4O2 (M=224.6g / mol) ESI-MS: 225[M+H] + R t (HPLC): 0.58 min (Method C)

[0078] Example XIV :1-(6-chloropyridazin-3-yl)-1H-imidazole-4-carboxamide [ka] To a solution of Example VI (1.00 g, 4.50 mmol) in 10 mL of DMF, DIPEA (2.30 mL, 13.4 mmol) and TBTU (1.40 g, 4.50 mmol) were added and stirred at RT for 10 minutes. Ammonium bicarbonate (1.10 g, 13.4 mmol) was added and the reaction mixture was stirred at RT for 1 hour. The mixture was quenched with ice, and the precipitate was filtered, washed, and dried to give 0.80 g of product.

[0079] C8H6ClNO (M=223.6g / mol) ESI-MS: 224[M+H] + R t (HPLC): 0.54 min (Method C)

[0080] Example XV :1-[6-(4-cyano-1H-imidazol-1-yl)pyridazin-3-yl]-1H-imidazole-4-carbonitrile [ka] To a solution of 1H-imidazole-4-carbonitrile (9.30 g, 99.9 mmol) in 100 mL of DMF, Example III (20.5 g, 99.9 mmol) and potassium carbonate (41.4 g, 299 mmol) are added and the reaction mixture is stirred for 18 hours at 50° C. 1H-imidazole-4-carbonitrile (5.00 g, 53.7 mmol) is added and the mixture is stirred at 50° C. for 3 days.

[0081] The mixture is quenched with water and the precipitate is filtered to give 25.8 g of product after drying. C 12 H6N8 (M = 262.2 g / mol) ESI-MS: 263 [M+H] + Rt (HPLC): 0.74 min (Method C)

[0082] Example XVI.1 :3-chloro-6-(4-chloro-1H-pyrazol-1-yl)pyridazine [ka] To a solution of 4-chloro-1H-pyrazole (688 mg, 7.00 mmol) in 5 mL of DMF, 3,6-dichloro-pyridazine (500 mg, 3.36 mmol) and cesium carbonate (2.40 g, 7.38 mmol) are added, and the reaction mixture is stirred overnight at RT. The mixture is quenched with water, and the precipitate is filtered to give 686 mg of product. C8H6N8 (M = 215.0 g / mol) ESI-MS: 216[M+H] + R t (HPLC): 0.51 min (Method A) The following compounds are prepared according to the general procedure described above (Example XVI.1).

[0083] [Table 20-1] [Table 20-2]

[0084] Example XVII :6-(pyrazin-2-yl)-2,3-dihydropyridazin-3-one [ka] To a solution of 2-oxoacetic acid hydrate (2.26 g, 25.0 mmol) in aqueous K2CO3 (6.79 g, 49.0 mmol) in 30 mL of water, acetylpyrazine (3.00 g, 24.6 mmol) is added. The mixture is stirred at RT for 6 h. Then, acetic acid (12.9 mL, 221 mmol) and hydrazine hydrate (1.42 mL, 29.0 mmol) are added, and the reaction mixture is refluxed for 2 h. The solution is cooled to RT and basified to pH 7 with K2CO3. The precipitate is filtered and dried in an oven at 40 °C to give 1.29 g of product.

[0085] C8H6N4O (M=174.1g / mol) ESI-MS: 175[M+H] + R t (HPLC): 0.23 min (Method A)

[0086] Example XVIII :3-chloro-6-(pyrazin-2-yl)pyridazine [ka] A solution of Example XVII (1.50 g, 6.03 mmol) in POCl (5.00 mL, 53.6 mmol) is stirred at 100° C. for 1 hour. The reaction mixture is evaporated, and the residue is diluted with DCM under cooling. 10 mL of saturated NaHCO solution is added, and this solution is added dropwise to cold saturated NaHCO solution under stirring until the solution becomes neutral. After 30 minutes, the solution is filtered through Celite, which is extracted with DCM. The organic layer is collected and dried, and the solvent is evaporated. The product is purified by column chromatography (silica gel, CH / EE (1 / 1)) to give 570 mg of product.

[0087] C8H6ClN4 (M = 192.6 g / mol) ESI-MS: 193[M+H] + R t (HPLC): 0.33 min (Method A)

[0088] Preparation of final compounds Example 1 5-[6-({1-[5-(difluoromethyl)pyridin-2-yl]-4-methyl-1H-1,2,3-triazol-5-yl}methoxy)pyridazin-3-yl]-1-methyl-1,2-dihydropyridin-2-one

[0089] [ka] To 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2-dihydropyridin-2-one (159 mg, 0.70 mmol) is added a solution of Example IX.1 (250 mg, 0.60 mmol) in 1.5 mL of methanol, 3 mL of 1,4 dioxane, 2 M aqueous sodium carbonate (0.60 mL, 1.10 mmol) and Pd-PEPPSI (9.50 mg 0.01 mmol) under argon, and the reaction mixture is stirred for 3 hours at 100° C. The mixture is purified by preparative HPLC to give 96.1 mg of product.

[0090] C 20 H 17 F2N7O2 (M = 425.4 g / mol) ESI-MS: 426[M+H] + R t (HPLC): 0.58 min (Method D) 1 H NMR (400 MHz, DMSO-d6) δ ppm 2.41 - 2.46 (m, 3 H) 3.48 - 3.57 (m, 3 H) 5.96 - 6.08 (m, 2 H) 6.47 - 6.58 (m, 1 H) 7.21 (t, J = 56 Hz 1 H) 7.23 (s, 1 H) 7.95 - 8.06 (m, 1 H) 8.13 - 8.22 (m, 2 H) 8.29 - 8.38 (m, 1 H) 8.51 (d, J=2.66 Hz, 1 H) 8.65 - 8.71 (m, 1 H) The following compounds are prepared according to the general procedure of Example 1 described above.

[0091] [Table 21-1] [Table 21-2] [Table 21-3] [Table 21-4] [Table 21-5] [Table 21-6] [Table 21-7] [Table 21-8] [Table 21-9] [Table 21-10] [Table 21-11]

[0092] For the example compounds, the reaction conditions in Table 2 were used. [Table 22] TIFF0007802256000086.tif231170

[0093] Example 36 [ka] To a solution of Example I (50.0 mg, 0.20 mmol) and Example XIV (46.5 mg, 0.20 mmol) in 2 mL of DMSO is added dropwise a solution of 2 mol / L sodium tert-pentoxide in Me-THF (83.9 μL, 0.20 mmol) at 0° C. The reaction mixture is stirred overnight at RT, then overnight at 50° C., and then at 75° C. for 3 days. The mixture is purified by preparative HPLC to give 3.20 mg of product.

[0094] C 18 H 15 F2N9O2 (M = 427.4 g / mol) ESI-MS: 428[M+H] + R t (HPLC): 0.77 min (Method C) The following compounds are prepared according to the general procedure of Example 36 described above.

[0095] [Table 23-1] [Table 23-2]

[0096] For Example Compounds 37 to 41, the reaction conditions in the table below were used. [Table 24] TIFF0007802256000091.tif98170

[0097] Example 42 1-[6-({1-[5-(difluoromethyl)pyridin-2-yl]-4-methyl-1H-1,2,3-triazol-5-yl}methoxy)pyridazin-3-yl]-1H-imidazole-4-carbonitrile

[0098] [ka] To a solution of Example I (200 mg, 1.00 mmol) in 5 mL of ACN, cesium carbonate (814 mg, 2.00 mmol) and Example XV (273 mg, 1.00 mmol) are added, and the mixture is stirred at 90° C. overnight. The reaction mixture is quenched with water, and the precipitate is filtered to obtain the crude product. The crude product is purified by silica gel column (CH / EE) and finally recrystallized in MeOH / EE / ether to obtain 151 mg of product.

[0099] C 18 H 13 F2N9O (M=409.3g / mol) ESI-MS: 410[M+H] + R t (HPLC): 0.50 min (Method A) 1 H NMR (400 MHz, DMSO-d6) δ ppm 2.34 - 2.48 (m, 3 H) 5.97 - 6.14 (m, 2 H) 7.22 (t, J = 56 Hz, 1H) 7.50 - 7.64 (m, 1 H) 8.16 - 8.19 (m, 1 H) 8.19 - 8.21 (m, 1 H) 8.31 - 8.43 (m, 1 H) 8.67 (d, J=1.14 Hz, 1 H) 8.73 (d, J=1.27 Hz, 1 H) 8.90 - 8.95 (m, 1 H) The following compounds 43-47 in the table below are prepared according to the general procedure described above in Example 42.

[0100] [Table 25-1] [Table 25-2] For Example Compounds 43 to 47, the reaction conditions in the table below were used.

[0101] [Table 26]

[0102] Example 48 3-({4-[5-(difluoromethyl)pyridin-2-yl]-1-methyl-1H-1,2,3-triazol-5-yl}methoxy)-6-(5-methyl-1H-1,2,4-triazol-1-yl)pyridazine

[0103] [ka] To a solution of Example VIII (200 mg, 0.83 mmol) and Example XI (163 mg, 0.83 mmol) in 10 mL of dioxane, sodium tert-pentoxide (101 mg, 0.92 mmol) is added. The reaction mixture is stirred at 90° C. overnight and then at RT over the weekend. The reaction mixture is diluted with water and the precipitate is filtered. The crude solid is recrystallized in MeOH to give 212 mg of product.

[0104] C 17 H 15 F2N9O (M=399.4g / mol) ESI-MS: 400[M+H] + R t (HPLC): 0.46 min (Method A) The following compounds 49 and 50 are prepared according to the general procedure described in Example 48 above.

[0105] [Table 27] For Example Compounds 49 to 50, the reaction conditions in the table below were used.

[0106] [Table 28]

[0107] Example 51 3-(4-chloro-1H-pyrazol-1-yl)-6-({4-[5-(difluoromethyl)pyridin-2-yl]-1-methyl-1H-1,2,3-triazol-5-yl}methoxy)pyridazine

[0108] [ka] To a solution of Example VIII (100 mg, 0.42 mmol) and Example XVI.1 (89.5 mg, 0.42 mmol) in 2 mL of DCM is added sodium hydride (21.8 mg, 0.50 mmol). The reaction mixture is stirred overnight at RT. The reaction mixture is directly purified by preparative HPLC to give 41.6 mg of product.

[0109] C 17 H 13 ClF2N8O (M=418.8g / mol) ESI-MS: 397[M+H] + R t (HPLC): 0.86 min (Method F) The following compounds are prepared according to the general procedure described previously (Example 51).

[0110] [Table 29]

[0111] For Example Compounds 52-53, the reaction conditions in the table below were used. [Table 30]

[0112] Example 54 3-({1-[5-(difluoromethyl)pyridin-2-yl]-4-methyl-1H-1,2,3-triazol-5-yl}methoxy)-6-(4-fluoro-1H-pyrazol-1-yl)pyridazine

[0113] [ka] To a solution of 4-fluoro-1H-pyrazole (6.00 mg, 0.10 mmol) in 1 mL of dioxane under argon, Example IX.1 (30.0 mg, 0.10 mmol), copper(I) iodide (5.10 mg, 0.03 mmol), potassium phosphate (57.3 mg, 0.30 mmol), and (1R,2R)-N,N'-dimethyl-1,2-cyclohexanediamine (8.50 μL, 0.05 mmol) are added. 100 μL of 25% ammonia is then added, and the mixture is stirred for another 15 min. The reaction mixture is filtered through an alox cartridge and an SPE-thiol cartridge, which is then purified by preparative HPLC to give 20.2 mg of product.

[0114] C 17 H 13 F3N8O (M=402.3g / mol) ESI-MS: 403[M+H] + R t (HPLC): 0.84 min (Method F) The following compound 55 is prepared according to the general procedure described in Example 54 above.

[0115] [Table 31]

[0116] For example compound 55, the following reaction conditions were used: [Table 32]

[0117] Example 56 3-({1-[5-(difluoromethyl)pyridin-2-yl]-4-methyl-1H-1,2,3-triazol-5-yl}methoxy)-6-(pyrazin-2-yl)pyridazine

[0118] [ka] To a solution of 2-tributylstannylpyrazine (83.0 mg, 0.23 mmol) in 2 mL of dioxane under argon, Example IX.2 (53.0 mg, 0.15 mmol), cesium fluoride (46.0 mg, 0.30 mmol) and xphos (26.0 mg, 0.03 mmol) are added. The reaction mixture is purified by preparative HPLC to give 17.0 mg of product.

[0119] C 18 H 14 F2N8O (M=396.3g / mol) ESI-MS: 397[M+H] + R t (HPLC): 0.92 min (Method G) 1 H NMR (400 MHz, DMSO-d6) δ ppm 2.47 (s, 3 H) 6.11 (s, 2 H) 7.22 (t, J = 56 Hz, 1H) 7.35 (d, J=9.25 Hz, 1 H) 8.20 (d, J=8.49 Hz, 1 H) 8.32 - 8.37 (m, 1 H) 8.39 (d, J=9.25 Hz, 1 H) 8.67 (d, J=1.14 Hz, 1 H) 8.74 - 8.84 (m, 2 H) 9.55 - 9.66 (m, 1 H)

[0120] Biological Examples Assay A: Human GABA A α5β3γ 2s to HEK cells expressing the receptor 3 H-flumazenil ( 3 In vitro inhibition of H-Ro (15-1788) binding The benzodiazepine modulator unit acts as an antagonist 3 It can be selectively labeled with 3H-flumazenil. for various subunit combinations 3 The affinity of H-flumazenil was α1β2γ2, α2β2γ2, α3β2γ2 and α5β2γ 2sThe reported potencies for the α4β2γ2 and α6β2γ2 receptors are 1.0 nM, 1.1 nM, 1.5 nM and 0.4 nM, respectively, and 107 nM and 90 nM for the α4β2γ2 and α6β2γ2 receptors (see Sieghart; Pharmacol. Rev. 1995 47 181-234). Mutation α5β3γ 2s GABA A The pharmacology of the receptor is similar to that of the wild-type receptor with respect to 3H-flumazenil binding.

[0121] Cell culture and membrane preparation Recombinant Human GABA A α5β3γ 2s HEK-293 cell lines with stable expression of the receptor (plasmid H46 / E9 / B10) were cultured in T175 polystyrene flasks or roller bottles (1700 cm 2 , Fisher Scientific CCI-431191) and cultured (37°C, 5% CO2) in Dulbecco's Modified Eagle's Medium (DMEM) containing GlutaMAX™ supplemented with 10% fetal bovine serum and one or both of the following antibiotics: hygromycin B (50 pg / ml, γ2 subunit) or G418 (0.5 mg / ml, Ω5 subunit). When the cultures reached confluence, the DMEM was removed and the cells were washed once in Dulbecco's phosphate-buffered saline (DPBS) (10 ml for T175 flasks, 50 ml for roller bottles). After adding DPBS to the cultures for approximately 5 minutes (10 ml for T175 flasks, 100 ml for roller bottles), the cells were easily detached from the surface by gently shaking or tapping the flask. The cell suspension was transferred to a Falcon tube and centrifuged at 23,500 × g for 10 minutes at 2°C. Using an Ultra-Turrax homogenizer, the pellet was washed once in 15 ml of Tris-citrate buffer (50 mM, pH 7.1) and centrifuged at 27,000 × g for 10 minutes at 2°C. The washed pellet was resuspended in 15 ml of Tris-citrate buffer and frozen at -80°C until the day of the binding experiment.

[0122] Assay On the day of the experiment, thaw the cell membrane preparation and centrifuge it at 27,000 x g for 10 min at 2 °C. Resuspend the pellet to 15-50 pg of protein per assay in Tris-citrate buffer using an Ultra-Turrax homogenizer and then use it in the binding assay. A 500 μl aliquot of the cell suspension was added to 25 μl of test compound solution and 3 25 μl of H-flumazenil (1 nM, final concentration) is added, mixed and incubated for 40 minutes at 2° C. Non-specific binding is determined using clonazepam (1 μM, final concentration). All test compound dilutions and assay incubations are performed in glass vials / 96-vial plates. 3 A solution of H-flumazenil is prepared at 22x the desired final concentration. Compounds are dissolved in 100% DMSO (10 mM stock solution), diluted in 48% ethanol-water, and tested in triplicate at serial 1:3 or 1:10 dilutions. When screening multiple compounds, only one concentration of each compound is tested in a single well. A reference compound is not always included, but in each experiment performed, total and nonspecific binding are compared to data obtained during assay validation.

[0123] The bond, The cells were terminated by either 1) rapid filtration onto Whatman GF / C glass fiber filters using a Brandel Cell Harvesting Apparatus, followed by five 1 ml washes with ice-cold buffer, or 2) rapid filtration onto UniFilter GF / C glass fiber filter plates using a Tomtec Cell Harvesting Apparatus, followed by approximately 5 ml washes with ice-cold buffer. 1) Separate large filters with Tri-Garb™ counting devices (PerkinElmer Life and Analytical Sciences), or 2) 96-well filter plates with a Topcount™ counting device (PerkinElmer Life and Analytical Sciences) The amount of radioactivity on the filters is determined by conventional liquid scintillation counting using a 1:1 ratio. Specific binding is total binding minus nonspecific binding.

[0124] calculation I C 50 ( 3 Before calculation of the concentration (µM) of test compound that inhibits the specific binding of H-flumazenil by 50%, 25-75% inhibition of specific binding must be obtained. IC for test compound 50 The value is the expression: B=100-(100*C n / (I C 50 n +C n )) is determined based on where B is the percentage binding of total specific binding, C is the concentration of test compound, and n is the Hill coefficient. For screening purposes, n is set to 1. IC 50 Values ​​are calculated from concentration-response curves by nonlinear regression using the curve-fitting program GraphPad Prism. The K value for a test compound is calculated according to the formula of Cheng and Prusoff: K=IC 50 / (1+L / K d ) Using IC 50 It can be calculated from the value During the ceremony, 3 K for H-flumazenil d is 0.36 nM, and L is the 3 Measured concentration of H-flumazenil.

[0125] result The potencies observed in Assay A, for example, for compounds 1, 13, 10 and 28 of WO 2020 / 016433, as well as for example compounds 42, 56, 5 and 55 of the present invention, are shown in the table below.

[0126] [Table 33] TIFF0007802256000107.tif67136

[0127] [Table 34] TIFF0007802256000109.tif239149

[0128] Assay B: α5β2γ2GABA A In vitro assessment of receptor modulation The modulatory effects of the compounds of formula (I) are determined by electrophysiological recordings in oocytes using the two-electrode voltage clamp (TEVC) technique. Oocytes are treated with human GABA in a 3:1:3 ratio. A cRNA for GABA receptor subunits α5, β2, and γ2 was injected, and submaximal EC2 was administered. 5-20 Modulatory effects are assessed by co-application of GABA (0.5 μM). As a standard, compounds are tested at five concentrations (3.16, 0.316, 0.0316, 0.00316, and 0.000316 μM) in each oocyte, starting with the lowest concentration. Background-subtracted peak current amplitudes are normalized to the respective GABA control current, converted to % change, and depicted + / - SEM as a function of increasing compound concentration. Plotted data points are fitted to an empirical Hill equation using nonlinear regression. Maximum effect (nadir) and efficacy (LogEC 50 ) results from this fitting routine.

[0129] [Table 35] TIFF0007802256000111.tif104155

[0130] These data demonstrate that the compounds of the present invention exhibit target binding and strong negative modulation of GABA receptor function. The data also demonstrate that the compounds exhibit GABA receptor activity, particularly in comparison to known compounds in WO 2020 / 016433. A It has improved properties with respect to 5R binding, which also indicates that the effective dose of the compound in treating the disease is lower (Ballard, TM, et al. (2009). RO4938581, a novel cognitive enhancer acting at GABA A α5 subunit-containing receptors. Psychopharmacology (2009) 202: 207-223; see also J. Pharmacol. Exp. Ther. (2006) 316: 1335-1345).

[0131] Assessment of efflux in Madin-Darby canine kidney (MDCK) cells transfected with the human MDR1 gene to assess brain penetration (Drug Metabolism and Disposition February 2008, 36 (2) 268-275; DOI: https: / / doi.org / 10.1124 / dmd.107.017434) The apparent permeability coefficient (PE) of compounds across MDCK-MDR1 cell monolayers was measured in the apical-basal (AB) and basolateral-apical (BA) transport directions (pH 7.4, 37°C). AB permeation (PEAB) represents drug absorption from blood to the brain, while BA permeation (PEBA) represents drug efflux from the brain back to the blood via both passive permeation and active transport mechanisms mediated primarily by overexpressed human MDR1 P-gp via efflux and uptake transporters expressed in MDCK-MDR1 cells. Compounds were assigned to permeation / absorption classes by comparing AB permeation with that of reference compounds with known in vitro permeation and oral absorption in humans. Identical or similar permeation in both transport directions indicates passive permeation, while unidirectional permeation indicates an additional active transport mechanism. A PEBA greater than PEAB indicates the involvement of active efflux mediated by MDR1 P-gp. Active transport is concentration-dependently saturated.

[0132] MDCK-MDR1 cells (1-2 x 10e5 cells / cm2 area) are seeded onto filter inserts (Costar transwell polycarbonate or PET filters, 0.4 µm pore size) and cultured for 7 days (DMEM). Subsequently, MDR1 expression is enhanced by culturing the cells with 5 mM sodium butyrate in complete medium for 2 days. Compounds are dissolved in a suitable solvent (e.g., DMSO, 1-20 mM stock solution). To prepare transport solution (0.1–300 μM compound, final DMSO <= 0.5%), dilute the stock solution with HTP-4 buffer (128.13 mM NaCl, 5.36 mM KCl, 1 mM MgSO, 1.8 mM CaCl, 4.17 mM NaHCO, 1.19 mM NaHPO x 7H2O, 0.41 mM NaHPO x 7H2O, 15 mM HEPES, 20 mM glucose, 0.25% BSA, pH 7.4). To measure AB or BA permeation (three filter replicates), respectively, transport solution (TL) was applied to the apical or basolateral donor side. The acceptor side contained the same buffer as the donor side. Samples were collected from the donor side at the beginning and end of the experiment and from the acceptor side at various intervals up to 2 h for concentration determination by HPLC-MS / MS or scintillation counting. The removed receiver volume is replaced with fresh receiver solution.

[0133] [Table 36] These data indicate that the compounds of the present invention have excellent brain penetration properties, along with low efflux rates from brain compartments.

[0134] Evaluation of metabolic stability in human liver microsomes (human MST) The metabolic stability of the compounds according to the invention can be studied as follows. Metabolic degradation of test compounds is analyzed at 37°C using pooled human liver microsomes. A final incubation volume of 100 μL per time point contains room temperature TRIS buffer pH 7.6 (0.1 M), MgCl (5 mM), microsomal protein (1 mg / mL), and a final concentration of 1 μM test compound. After a short preincubation period at 37°C, the reaction is initiated by the addition of beta-nicotinamide adenine dinucleotide phosphate, reduced form (NADPH, 1 mM) and terminated after various time points by transferring aliquots to solvent. After centrifugation (10,000 g, 5 min), aliquots of the supernatant are analyzed by LCMS / MS for the amount of parent compound. The half-life (t) is determined from the slope of a semi-logarithmic plot of the concentration-time profile.

[0135] [Table 37]

[0136] GABA containing the α5 subunit A In view of their ability to modulate the activity of the receptor and their advantageous pharmacokinetic properties, the compounds of general formula (I) according to the present invention, or physiologically acceptable salts thereof, are suitable for the modulation of GABA receptors containing the α5 subunit. AThe compounds according to the invention, including their physiologically acceptable salts, are therefore suitable for the treatment and / or prophylactic treatment of all diseases or conditions that can be influenced by the modulation of receptors.Therefore, the compounds according to the invention, including their physiologically acceptable salts, are useful for the treatment of diseases, in particular acute neurological disorders, chronic neurological disorders, cognitive disorders, Alzheimer's disease, memory deficits, schizophrenia, positive, negative and / or cognitive symptoms associated with schizophrenia, cognitive impairment associated with schizophrenia, bipolar disorder, autism, Down's syndrome, neurofibromatosis type I, postoperative cognitive decline, sleep disorders, circadian rhythm disorders, amyotrophic lateral sclerosis, dementia caused by AIDS, psychotic disorders, substance-induced psychotic disorders, anxiety disorders, generalized anxiety disorder, panic disorder, delusional disorder, obsessive-compulsive disorder, acute stress disorder, drug dependence, movement disorders, Parkinson's disease, restless legs syndrome, cognitive deficit disorders, It is particularly suitable for the prevention or treatment of multi-infarct dementia, mood disorders, depression, major depressive disorder, neuropsychiatric conditions, psychosis, attention deficit hyperactivity disorder, neuropathic pain, stroke, attention disorders, eating disorders, anorexia, anorexia nervosa, cachexia, weight loss, muscle atrophy, pain conditions, chronic pain, nociceptive pain, post-operative pain, knee osteoarthritis pain, rheumatoid arthritis pain, musculoskeletal pain, burn pain, eye pain, inflammatory pain, fracture pain, hyperalgesia, neuropathic pain, herpes-related pain, HIV-associated neuropathic pain, traumatic nerve injury, post-traumatic brain injury recovery, post-stroke pain, post-ischemic pain, fibromyalgia, chronic headache, migraine, tension headache, diabetic neuropathic pain, phantom limb pain, visceral pain and cutaneous pain. The compounds according to the invention, including the physiologically acceptable salts thereof, are even more suitable for the treatment of inter alia cognitive disorders, post-operative cognitive decline, Alzheimer's disease, schizophrenia, positive, negative and / or cognitive symptoms associated with schizophrenia, cognitive impairment associated with schizophrenia, cognitive deficits associated with Down's syndrome, cognitive deficits associated with autism, cognitive deficits associated with neurofibromatosis type I, or cognitive deficits after stroke.

[0137] In a further aspect of the present invention, the present invention relates to a method for the treatment or prevention of the above-mentioned diseases and conditions, the method comprising the administration to a human of an effective amount of a compound of general formula (I), or a pharmaceutically acceptable salt thereof. The daily dose range of the compounds of general formula (I) that can be administered is usually 0.1 to 1000 mg, preferably 1 to 500 mg, by oral route, administered in each case 1 to 4 times a day. Each dosage unit may conveniently contain from 0.1 to 500 mg, preferably from 1 to 100 mg.

[0138] The actual pharmaceutically effective amount or therapeutic dosage will of course depend on factors known by those skilled in the art, such as the age and weight of the patient, the route of administration, and the severity of the disease, etc. In any case, the combination will be administered in a dosage and manner that allows a pharmaceutically effective amount to be delivered based on the patient's unique condition. Suitable formulations for administering compounds of Formula I, including pharmaceutically acceptable salts thereof, will be apparent to those skilled in the art and include, for example, tablets, pills, capsules, suppositories, lozenges, troches, liquids, syrups, elixirs, sachets, injectables, inhalants, powders, etc. The content of the pharmaceutically active compound should range from 0.1 to 95% by weight, preferably 5.0 to 90% by weight, of the total composition. Suitable tablets are obtained, for example, by mixing one or more compounds according to formula I with known excipients, such as inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and / or lubricants. Tablets may consist of several layers.

[0139] For this purpose, the compounds of formula I prepared according to the present invention may be formulated, optionally together with other active substances, with one or more inert conventional carriers and / or diluents, for example, corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, citric acid, tartaric acid, water, polyvinylpyrrolidone, water / ethanol, water / glycerol, water / sorbitol, water / polyethylene glycol, propylene glycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fats, or suitable mixtures thereof.

[0140] The compounds according to the invention may be used in conjunction with other active substances, in particular for the treatment and / or prevention of the diseases and conditions mentioned above. A list of examples includes donepezil, memantine, acetazolamide, carbamazepine, eslicarbazepine acetate, ethosuximide, gabapentin, lacosamide, lamotrigine, levetiracetam, brivaracetam, nitrazepam, oxcarbazepine, perampanel, piracetam, phenobarbital, phenytoin, pregabalin, primidone, rufinamide, sodium valproate, stiripentol, tiagabine, topi lamate, vigabatrin, zonisamide, levodopa, carbidopa, haloperidol, loxapine, thioridazine, molindone, thiothixene, fluphenazine, mesoridazine, trifluoperazine, perphenazine, chlorpromazine, aripiprazole, asenapine maleate, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone, and zolpidem.

[0141] Dosages for the combination partners mentioned above are usefully 1 / 5 of the minimum normally recommended dose to 1 / 1 of the maximum normally recommended dose. Therefore, in another aspect, the present invention relates to the use of a compound according to the invention or a pharmaceutically acceptable salt thereof, in combination with at least one of the active substances described above as combination partners, for preparing a pharmaceutical composition suitable for the treatment or prevention of the diseases or conditions described above.

[0142] The use of the compounds according to the invention in combination with another active substance can be carried out simultaneously or at different times, but particularly within a short time. When they are administered simultaneously, the two active substances are administered to the patient together, but when they are used at different times, the two active substances are administered to the patient within a period of not more than 12 hours, but particularly not more than 6 hours.

[0143] Consequently, in another aspect, the present invention relates to a pharmaceutical composition comprising a compound according to the invention or a pharmaceutically acceptable salt thereof and at least one of the active substances described above as combination partners, optionally together with one or more inert carriers and / or diluents. The compounds according to the invention may be present together in one formulation, for example a tablet or capsule, or may be present separately in two identical or different formulations, for example as a so-called kit of parts. Another aspect of the present invention may be as follows. [1] A compound having the formula (I) or a salt thereof. [ka] (I) (In the formula, Xa and Xb are different from each other and represent C or N; R1 is a substituted phenyl or a 5- or 6-membered substituted heterocyclyl ring containing 1, 2, or 3 heteroatoms. [2] The compound or salt thereof according to [1] above, wherein either Xa or Xb is C. [3] R1 is Carbamoyl-substituted phenyl [ka] and Unsubstituted 2-pyridones or 2-pyridones substituted with halogens such as fluorine or substituted on the nitrogen with methyl or ethyl [ka] The compound or salt thereof according to [1] above, selected from the group consisting of: [4] R1 is NC- or -thiomethylato-, amino-, methyl-amino- or -methylsulfonyl or halogen-substituted 3-pyridyl, [ka] The compound or salt thereof according to [1] above, [5] R1 is Substituted or unsubstituted pyrimidinyl-(C 1-6 -substituted with alkyl-, amino, hydroxymethyl) or pyrazinyl-, [ka] The compound or salt thereof according to [1] above, [6] R1 is C 1-6 -Alkyl- or NC-CH 2 -CH 2 -substituted pyrrolyl-, and C 1-6 -Alkyl-, C 3-5 -cycloalkyl-, NC-CH 2 -CH 2 pyrazolyl-substituted with -, -amino, -methyl-amino, or -halogen

change

change

change

change

change

[10] R1 is carbamoyl-substituted phenyl, unsubstituted 2-pyridones or substituted with halogens such as fluorine or substituted on the nitrogen by methyl or ethyl; NC- or thiomethylate-, amino-, methylamino-, methylsulfonyl- or halogen-substituted 3-pyridyl, Unsubstituted pyrimidinyl-, or C 1-6 -alkyl-, amino-, -hydroxymethyl-substituted pyrimidinyl- or pyrazinyl-, C 1-6 -Alkyl- or NC-CH 2 -CH 2 -substituted pyrrolyl-, and C 1-6 -Alkyl-, C 3-5 -cycloalkyl-, NC-CH 2 -CH 2 -, amino-, methyl-amino-, or -pyrazolyl- substituted with halogen; C 1-6 -Alkyl-, carbamoyl-, NC-CH 2 -CH 2 -, amino- or -methylamino-substituted imidazolyl-, C, such as unsubstituted triazolyl- or methyl 1-3 -alkyl-substituted triazolyl-, Methyl-substituted oxazolyl- and NC-CH 2 -CH 2 -substituted thiophenyl- The compound or salt thereof according to [1] above, selected from the group consisting of: 〔11〕 Table 1-1 Table 1-2 Table 1-3 Table 1-4 Table 1-5 Table 1-6 Table 1-7 Table 1-8 Table 1-9 The compound or salt thereof according to [1] above, selected from the group consisting of:

[12] A salt of the compound according to any one of [1] to

[11] above for use as a pharmaceutical.

[13] A medicine prepared using the compound or salt thereof according to any one of [1] to

[11] above.

[14] The compound or salt thereof according to the above [1], wherein the formula (I) is any one of the formulae of compounds 22 to 56 and 39.

[15] A method for preparing the compound according to [1] above, comprising the following chemical reaction pathway: (a)

change

change

[16] A method for preparing the compound according to [1] above, comprising the following chemical reaction pathway:

change

change

[17] A pharmaceutical composition comprising at least one compound or a pharmaceutically acceptable salt thereof according to any one of [1] to

[11] above, together with one or more pharmaceutically acceptable carriers.

[18] Acute neurological disorders, chronic neurological disorders, cognitive impairment, Alzheimer's disease, memory deficits, schizophrenia, positive, negative and / or cognitive symptoms associated with schizophrenia, cognitive impairment associated with schizophrenia, bipolar disorder, autism, Down's syndrome, neurofibromatosis type 1, postoperative cognitive decline, sleep disorders, circadian rhythm disorders, amyotrophic lateral sclerosis, AIDS-induced dementia, psychotic disorders, substance-induced psychotic disorders, anxiety disorders, generalized anxiety disorder, panic disorder, delusional disorder, obsessive-compulsive disorder, acute stress disorder, drug dependence, movement disorders, Parkinson's disease, restless legs syndrome, cognitive deficit disorders, multi-infarct dementia, mood disorders, depression, major depressive disorder The pharmaceutical composition according to

[17] above, for the treatment or prevention of disorders, neuropsychiatric conditions, psychosis, attention deficit hyperactivity disorder, neuropathic pain, stroke, attention disorders, eating disorders, anorexia, anorexia nervosa, cachexia, weight loss, muscle atrophy, pain conditions, chronic pain, nociceptive pain, post-operative pain, knee osteoarthritis pain, rheumatoid arthritis pain, musculoskeletal pain, burn pain, eye pain, inflammatory pain, fracture pain, hyperalgesia, neuropathic pain, herpes-related pain, HIV-associated neuropathic pain, traumatic nerve injury, traumatic brain injury recovery, post-stroke pain, post-ischemic pain, fibromyalgia, chronic headache, migraine, tension headache, diabetic neuropathic pain, phantom limb pain, visceral pain, and cutaneous pain.

[19] The pharmaceutical composition according to

[18] above, comprising a therapeutically effective amount of the compound according to any one of [1] to

[11] above or a pharmaceutically acceptable salt thereof, 0.1 to 1000 mg, preferably 1 to 500 mg.

[20] The compound according to any one of [1] to

[11] above, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to

[17] above, for use in the prevention or treatment of cognitive impairment, postoperative cognitive decline, Alzheimer's disease, schizophrenia, positive, negative and / or cognitive symptoms associated with schizophrenia, cognitive impairment associated with schizophrenia, cognitive deficits associated with Down's syndrome, cognitive deficits associated with autism, cognitive deficits associated with neurofibromatosis type I, or cognitive deficits after stroke.

Claims

1. A compound having the formula (I) or a salt thereof: 【Chemistry 1】 (I) (In the formula, Xa and Xb are different from each other and represent C or N; R1 is an unsubstituted 2-pyridone, or a 2-pyridone substituted with a halogen such as fluorine, or a 2-pyridone substituted on the nitrogen with methyl- or ethyl-.

2. R1 is 【Chemistry 2】 2. The compound according to claim 1, or a salt thereof, 【Request Item 3】 【Table 1】 2. The compound according to claim 1, or a salt thereof, selected from the group consisting of:

4. The compound or salt thereof according to claim 3, wherein the compound is compound 1.

5. The compound or salt thereof according to claim 3, wherein the compound is compound 20.

6. The compound or salt thereof according to claim 3, wherein the compound is compound 21.

7. A pharmaceutical composition comprising a salt of the compound according to any one of claims 1 to 6.

8. A pharmaceutical composition comprising the compound or salt thereof according to any one of claims 1 to 6.

9. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers.

10. acute neurological disorders, chronic neurological disorders, cognitive impairment, Alzheimer's disease, memory deficits, schizophrenia, positive, negative and / or cognitive symptoms associated with schizophrenia, cognitive impairment associated with schizophrenia, bipolar disorder, autism, Down's syndrome, neurofibromatosis type 1, postoperative cognitive decline, sleep disorders, circadian rhythm disorders, amyotrophic lateral sclerosis, AIDS-induced dementia, psychotic disorders, substance-induced psychotic disorders, anxiety disorders, generalized anxiety disorder, panic disorder, delusional disorder, obsessive-compulsive disorder, acute stress disorder, drug dependence, movement disorders, Parkinson's disease, restless legs syndrome, cognitive deficit disorders, multi-infarct dementia, mood disorders, depression, major depressive disorder, neuropsychiatric conditions 10. The pharmaceutical composition of any one of claims 7 to 9 for use in the treatment or prevention of rheumatoid arthritis, psychosis, attention deficit hyperactivity disorder, neuropathic pain, stroke, attention disorders, eating disorders, anorexia, anorexia nervosa, cachexia, weight loss, muscle atrophy, pain conditions, chronic pain, nociceptive pain, post-operative pain, knee osteoarthritis pain, rheumatoid arthritis pain, musculoskeletal pain, burn pain, ocular pain, inflammatory pain, fracture pain, hyperalgesia, neuropathic pain, herpes-related pain, HIV-associated neuropathic pain, traumatic nerve injury, traumatic brain injury recovery, post-stroke pain, post-ischemic pain, fibromyalgia, chronic headache, migraine, tension headache, diabetic neuropathic pain, phantom limb pain, visceral pain and cutaneous pain.

11. 11. The pharmaceutical composition according to claim 10, comprising a therapeutically effective amount of 0.1 to 1000 mg of the compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof.

12. 11. The pharmaceutical composition of claim 10 for use in the prevention or treatment of cognitive impairment, post-operative cognitive decline, Alzheimer's disease, schizophrenia, positive, negative and / or cognitive symptoms associated with schizophrenia, cognitive impairment associated with schizophrenia, cognitive deficits associated with Down's syndrome, cognitive deficits associated with autism, cognitive deficits associated with neurofibromatosis type I, or cognitive deficits after stroke.

Images